Malaria — PvRBP3 mRNA Vaccine Candidate

Plasmodium vivax malaria depends on reticulocyte invasion mediated by parasite proteins such as reticulocyte-binding protein 3 (PvRBP3). This design targets PvRBP3 as the vaccine antigen: immunogenic B-cell and T-cell epitopes are predicted on the PvRBP3 protein, linked into a multi-epitope construct, and encoded in a codon-optimized mRNA of 1,253 nucleotides for conceptual lipid nanoparticle delivery. The aim is broad antigen recognition of a key invasion protein within a Plasmodium vivax vaccine research framework.

Enlarge

Original uploaded scientific infographic — use the Enlarge button for a full-size view.

1. 1

   Target selection — PvRBP3, a key invasion protein of Plasmodium vivax, is chosen as the vaccine target protein.

2. 2

   Epitope selection — identify immunogenic B-cell and T-cell epitopes on PvRBP3 (12 MHC-I selected, 8 MHC-II selected, plus B-cell epitopes).

3. 3

   Multi-epitope construct — link selected epitopes with appropriate linker sequences into a multi-epitope PvRBP3 construct.

4. 4

   Codon optimization & mRNA design — optimize the coding sequence and finalize the mRNA design for high predicted expression (1,253 nt).

5. 5

   Formulation concept — conceptual mRNA encapsulation in an LNP for delivery.

6. 6

   Immune activation modeling — model multi-epitope antigen presentation activating CD8+ (cytotoxic) and CD4+ (helper) T cells.

1. 1

   The codon-optimized multi-epitope mRNA is delivered (conceptually) in an LNP.

2. 2

   Host antigen-presenting cells translate the mRNA and present PvRBP3 epitopes.

3. 3

   CD8+ T cells recognize MHC-I presented epitopes and mount a modeled cytotoxic response.

4. 4

   CD4+ T cells recognize MHC-II presented epitopes and provide a modeled helper response.

5. 5

   The predicted outcome is broad antigen recognition of a key malaria invasion protein — potential support for anti-malaria vaccine research, not a proven or approved vaccine.

All steps describe intended, modeled or proposed behavior — no effect above is experimentally proven or clinically demonstrated.

Malaria — Computational vaccine design

These projects are scientific research designs and computational proof-of-concept studies. They are not approved medical products, experimentally validated cures, or guarantees of therapeutic effectiveness.